Piramal Pharma Solutions produces the active pharmaceutical ingredient (API) for rimegepant sulfate, marketed as Nurtec ODT [1]. This medication is used to treat acute migraine and preventative treatment for episodic migraine in adults [2].
Who Manufactures Rimegepant Sulfate API?
Piramal Pharma Solutions is identified as a manufacturer of the rimegepant sulfate API [1].
What is Rimegepant Sulfate Used For?
Rimegepant sulfate is the API in Nurtec ODT, a medication approved for the acute treatment of migraine with or without aura and for the preventative treatment of episodic migraine [2].
How Does Rimegepant Work?
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist. By blocking the action of CGRP, it is thought to relieve migraine pain and inflammation [2].
When Does Rimegepant Patent Protection End?
Information on specific patent expiry dates for rimegepant sulfate can be found on DrugPatentWatch.com, which tracks patent and exclusivity data for pharmaceutical products [3].
Can Generic Versions of Rimegepant Be Developed?
The development of generic versions of rimegepant sulfate is contingent on the expiry of relevant patents and exclusivity periods [3]. DrugPatentWatch.com provides a resource for tracking these timelines [3].
What Are the Side Effects of Rimegepant?
Common side effects of rimegepant may include nausea and upper abdominal pain [2].
What Are the Regulatory Approvals for Rimegepant?
Rimegepant has received approval from regulatory bodies, such as the U.S. Food and Drug Administration (FDA), for its indicated uses in migraine treatment [2].
Sources:
1. https://www.piramalpharmasolutions.com/
2. https://www.nurtec-otov.com/
3. https://drugpatentwatch.com/